{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:25:23Z","timestamp":1789575923246,"version":"build-2803163510"},"reference-count":123,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s00213-021-06049-6","type":"journal-article","created":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T22:03:31Z","timestamp":1642025011000},"page":"1907-1932","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["Assessing the risk\u2013benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research"],"prefix":"10.1007","volume":"239","author":[{"given":"David","family":"Bender","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8031-4354","authenticated-orcid":false,"given":"David J.","family":"Hellerstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,13]]},"reference":[{"issue":"7","key":"6049_CR1","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/jat\/bkaa145","volume":"45","author":"R Aakeroy","year":"2020","unstructured":"Aakeroy R et al (2020) Severe neurological sequelae after a recreational dose of LSD. J Anal Toxicol 45(7):e1\u2013e3","journal-title":"J Anal Toxicol"},{"issue":"3281","key":"6049_CR2","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1126\/science.126.3281.1020","volume":"126","author":"HA Abramson","year":"1957","unstructured":"Abramson HA et al (1957) Production of tolerance to psychosis-producing doses of lysergic acid diethylamide. Science 126(3281):1020","journal-title":"Science"},{"issue":"2","key":"6049_CR3","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1021\/acsptsci.1c00014","volume":"4","author":"JS Aday","year":"2021","unstructured":"Aday JS et al (2021) Predicting reactions to psychedelic drugs: a systematic review of states and traits related to acute drug effects. ACS Pharmacol Transl Sci 4(2):424\u2013435","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"2","key":"6049_CR4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/acps.13249","volume":"143","author":"KAA Andersen","year":"2021","unstructured":"Andersen KAA et al (2021) Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies. Acta Psychiatr Scand 143(2):101\u2013118","journal-title":"Acta Psychiatr Scand"},{"key":"6049_CR5","doi-asserted-by":"publisher","first-page":"100538","DOI":"10.1016\/j.eclinm.2020.100538","volume":"27","author":"BT Anderson","year":"2020","unstructured":"Anderson BT et al (2020a) Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study. EClinicalMedicine 27:100538","journal-title":"EClinicalMedicine"},{"issue":"10","key":"6049_CR6","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S2215-0366(20)30146-2","volume":"7","author":"BT Anderson","year":"2020","unstructured":"Anderson BT, Danforth AL, Grob CS (2020b) Psychedelic medicine: safety and ethical concerns. Lancet Psychiatry 7(10):829\u2013830","journal-title":"Lancet Psychiatry"},{"issue":"12","key":"6049_CR7","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1177\/0269881116678781","volume":"30","author":"FS Barrett","year":"2016","unstructured":"Barrett FS et al (2016) The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms. J Psychopharmacol 30(12):1279\u20131295","journal-title":"J Psychopharmacol"},{"issue":"1","key":"6049_CR8","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1038\/s41598-020-59282-y","volume":"10","author":"FS Barrett","year":"2020","unstructured":"Barrett FS et al (2020) Emotions and brain function are altered up to one month after a single high dose of psilocybin. Sci Rep 10(1):2214","journal-title":"Sci Rep"},{"key":"6049_CR9","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1177\/0022167817706884","volume":"57","author":"AB Belser","year":"2017","unstructured":"Belser AB, Agin-Liebes G, Swift TC, Terrana S, Devenot N, Friedman HL, Guss J, Bossis A, Ross S (2017) Patient experiences of psilocybin-assisted psychotherapy: an interpretative phenomenological analysis. J Humanist Psychol 57:354\u2013388","journal-title":"J Humanist Psychol"},{"issue":"4","key":"6049_CR10","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/S0033-3182(10)70711-8","volume":"51","author":"Z Berrens","year":"2010","unstructured":"Berrens Z, Lammers J, White C (2010) Rhabdomyolysis after LSD ingestion. Psychosomatics 51(4):356-3563 e3","journal-title":"Psychosomatics"},{"issue":"6","key":"6049_CR11","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1097\/00063110-200512000-00011","volume":"12","author":"M Bickel","year":"2005","unstructured":"Bickel M et al (2005) Severe rhabdomyolysis, acute renal failure and posterior encephalopathy after \u201cmagic mushroom\u201d abuse. Eur J Emerg Med 12(6):306\u2013308","journal-title":"Eur J Emerg Med"},{"issue":"3","key":"6049_CR12","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1177\/0269881114565144","volume":"29","author":"MP Bogenschutz","year":"2015","unstructured":"Bogenschutz MP et al (2015) Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol 29(3):289\u2013299","journal-title":"J Psychopharmacol"},{"key":"6049_CR13","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3389\/fphar.2018.00100","volume":"9","author":"MP Bogenschutz","year":"2018","unstructured":"Bogenschutz MP et al (2018) Clinical interpretations of patient experience in a trial of psilocybin-assisted psychotherapy for alcohol use disorder. Front Pharmacol 9:100","journal-title":"Front Pharmacol"},{"issue":"1\u20132","key":"6049_CR14","first-page":"229","volume":"73","author":"KR Bonson","year":"1996","unstructured":"Bonson KR, Murphy DL (1996) Alterations in responses to LSD in humans associated with chronic administration of tricyclic antidepressants, monoamine oxidase inhibitors or lithium. Behav Brain Res 73(1\u20132):229\u2013233","journal-title":"Behav Brain Res"},{"issue":"6","key":"6049_CR15","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/0893-133X(95)00145-4","volume":"14","author":"KR Bonson","year":"1996","unstructured":"Bonson KR, Buckholtz JW, Murphy DL (1996) Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans. Neuropsychopharmacology 14(6):425\u2013436","journal-title":"Neuropsychopharmacology"},{"issue":"1\u20132","key":"6049_CR16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3109\/15563659809162584","volume":"36","author":"KS Borowiak","year":"1998","unstructured":"Borowiak KS, Ciechanowski K, Waloszczyk P (1998) Psilocybin mushroom (Psilocybe semilanceata) intoxication with myocardial infarction. J Toxicol Clin Toxicol 36(1\u20132):47\u201349","journal-title":"J Toxicol Clin Toxicol"},{"issue":"8","key":"6049_CR17","doi-asserted-by":"publisher","first-page":"e42421","DOI":"10.1371\/journal.pone.0042421","volume":"7","author":"JC Bouso","year":"2012","unstructured":"Bouso JC et al (2012) Personality, psychopathology, life attitudes and neuropsychological performance among ritual users of Ayahuasca: a longitudinal study. PLoS One 7(8):e42421","journal-title":"PLoS One"},{"key":"6049_CR18","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.neubiorev.2018.02.004","volume":"87","author":"JC Bouso","year":"2018","unstructured":"Bouso JC et al (2018) Serotonergic psychedelics and personality: A systematic review of contemporary research. Neurosci Biobehav Rev 87:118\u2013132","journal-title":"Neurosci Biobehav Rev"},{"issue":"12","key":"6049_CR19","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s40262-017-0540-6","volume":"56","author":"RT Brown","year":"2017","unstructured":"Brown RT et al (2017) Pharmacokinetics of escalating doses of oral psilocybin in healthy adults. Clin Pharmacokinet 56(12):1543\u20131554","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"6049_CR20","first-page":"137","volume":"3","author":"NS Buckholtz","year":"1990","unstructured":"Buckholtz NS et al (1990) Lysergic acid diethylamide (LSD) administration selectively downregulates serotonin2 receptors in rat brain. Neuropsychopharmacology 3(2):137\u2013148","journal-title":"Neuropsychopharmacology"},{"issue":"7842","key":"6049_CR21","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41586-020-3008-z","volume":"589","author":"LP Cameron","year":"2021","unstructured":"Cameron LP et al (2021) A non-hallucinogenic psychedelic analogue with therapeutic potential. Nature 589(7842):474\u2013479","journal-title":"Nature"},{"issue":"12","key":"6049_CR22","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1177\/0269881116662634","volume":"30","author":"TM Carbonaro","year":"2016","unstructured":"Carbonaro TM et al (2016) Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. J Psychopharmacol 30(12):1268\u20131278","journal-title":"J Psychopharmacol"},{"issue":"2","key":"6049_CR23","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s00213-017-4769-4","volume":"235","author":"TM Carbonaro","year":"2018","unstructured":"Carbonaro TM et al (2018) Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences. Psychopharmacology 235(2):521\u2013534","journal-title":"Psychopharmacology"},{"issue":"9","key":"6049_CR24","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1177\/0269881117725915","volume":"31","author":"RL Carhart-Harris","year":"2017","unstructured":"Carhart-Harris RL, Nutt DJ (2017) Serotonin and brain function: a tale of two receptors. J Psychopharmacol 31(9):1091\u20131120","journal-title":"J Psychopharmacol"},{"issue":"6","key":"6049_CR25","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1073\/pnas.1119598109","volume":"109","author":"RL Carhart-Harris","year":"2012","unstructured":"Carhart-Harris RL et al (2012) Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A 109(6):2138\u20132143","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6049_CR26","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fnhum.2014.00020","volume":"8","author":"RL Carhart-Harris","year":"2014","unstructured":"Carhart-Harris RL et al (2014) The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. Front Hum Neurosci 8:20","journal-title":"Front Hum Neurosci"},{"issue":"7","key":"6049_CR27","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","volume":"3","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris RL et al (2016a) Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 3(7):619\u2013627","journal-title":"Lancet Psychiatry"},{"issue":"17","key":"6049_CR28","doi-asserted-by":"publisher","first-page":"4853","DOI":"10.1073\/pnas.1518377113","volume":"113","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris RL et al (2016b) Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proc Natl Acad Sci U S A 113(17):4853\u20134858","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"6049_CR29","doi-asserted-by":"publisher","first-page":"13187","DOI":"10.1038\/s41598-017-13282-7","volume":"7","author":"RL Carhart-Harris","year":"2017","unstructured":"Carhart-Harris RL et al (2017) Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Sci Rep 7(1):13187","journal-title":"Sci Rep"},{"issue":"7","key":"6049_CR30","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1177\/0269881118754710","volume":"32","author":"RL Carhart-Harris","year":"2018","unstructured":"Carhart-Harris RL et al (2018a) Psychedelics and the essential importance of context. J Psychopharmacol 32(7):725\u2013731","journal-title":"J Psychopharmacol"},{"issue":"2","key":"6049_CR31","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","volume":"235","author":"RL Carhart-Harris","year":"2018","unstructured":"Carhart-Harris RL et al (2018b) Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology 235(2):399\u2013408","journal-title":"Psychopharmacology"},{"issue":"15","key":"6049_CR32","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","volume":"384","author":"R Carhart-Harris","year":"2021","unstructured":"Carhart-Harris R et al (2021) Trial of psilocybin versus escitalopram for depression. N Engl J Med 384(15):1402\u20131411","journal-title":"N Engl J Med"},{"key":"6049_CR33","first-page":"268","volume-title":"Etude pharmacologique de la psilocybine Les champignons hallucinogenes du mexique","author":"AU Cerletti","year":"1958","unstructured":"Cerletti AU (1958) Etude pharmacologique de la psilocybine Les champignons hallucinogenes du mexique. Museum de historie naturelle, Paris, pp 268\u2013271"},{"issue":"1","key":"6049_CR34","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/cpdd.796","volume":"10","author":"E Dahmane","year":"2021","unstructured":"Dahmane E, Hutson PR, Gobburu JVS (2021) Exposure-response analysis to assess the concentration-QTc relationship of psilocybin\/psilocin. Clin Pharmacol Drug Dev 10(1):78\u201385","journal-title":"Clin Pharmacol Drug Dev"},{"key":"6049_CR35","doi-asserted-by":"crossref","unstructured":"Dakwar E et al (2019) A single ketamine infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: a randomized clinical trial. Am J Psychiatry 176(11):923\u2013930","DOI":"10.1176\/appi.ajp.2019.18101123"},{"issue":"5","key":"6049_CR36","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","volume":"78","author":"AK Davis","year":"2020","unstructured":"Davis AK et al (2020) Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry 78(5):481\u2013489","journal-title":"JAMA Psychiatry"},{"issue":"3982","key":"6049_CR37","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1126\/science.172.3982.431","volume":"172","author":"NI Dishotsky","year":"1971","unstructured":"Dishotsky NI et al (1971) LSD and genetic damage. Science 172(3982):431\u2013440","journal-title":"Science"},{"issue":"2","key":"6049_CR38","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/00008877-200403000-00007","volume":"15","author":"WE Fantegrossi","year":"2004","unstructured":"Fantegrossi WE, Woods JH, Winger G (2004) Transient reinforcing effects of phenylisopropylamine and indolealkylamine hallucinogens in rhesus monkeys. Behav Pharmacol 15(2):149\u2013157","journal-title":"Behav Pharmacol"},{"key":"6049_CR39","doi-asserted-by":"publisher","DOI":"10.2307\/j.ctvbcd20q","volume-title":"Bwiti: an ethnography of the religious imagination in Africa","author":"JW Fernandez","year":"2019","unstructured":"Fernandez JW (2019) Bwiti: an ethnography of the religious imagination in Africa. Princeton University Press"},{"issue":"3","key":"6049_CR40","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2174\/1874473708666150107121331","volume":"7","author":"A Garcia-Romeu","year":"2014","unstructured":"Garcia-Romeu A, Griffiths RR, Johnson MW (2014) Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr Drug Abuse Rev 7(3):157\u2013164","journal-title":"Curr Drug Abuse Rev"},{"issue":"9","key":"6049_CR41","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1177\/0269881119845793","volume":"33","author":"A Garcia-Romeu","year":"2019","unstructured":"Garcia-Romeu A et al (2019a) Cessation and reduction in alcohol consumption and misuse after psychedelic use. J Psychopharmacol 33(9):1088\u20131101","journal-title":"J Psychopharmacol"},{"key":"6049_CR42","doi-asserted-by":"publisher","first-page":"955","DOI":"10.3389\/fpsyt.2019.00955","volume":"10","author":"A Garcia-Romeu","year":"2019","unstructured":"Garcia-Romeu A et al (2019b) Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey. Front Psychiatry 10:955","journal-title":"Front Psychiatry"},{"issue":"4","key":"6049_CR43","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1177\/0269881121991822","volume":"35","author":"A Garcia-Romeu","year":"2021","unstructured":"Garcia-Romeu A et al (2021) Optimal dosing for psilocybin pharmacotherapy: considering weight-adjusted and fixed dosing approaches. J Psychopharmacol 35(4):353\u2013361","journal-title":"J Psychopharmacol"},{"issue":"7","key":"6049_CR44","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/NMD.0000000000000113","volume":"202","author":"P Gasser","year":"2014","unstructured":"Gasser P et al (2014) Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis 202(7):513\u2013520","journal-title":"J Nerv Ment Dis"},{"issue":"1","key":"6049_CR45","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0269881114555249","volume":"29","author":"P Gasser","year":"2015","unstructured":"Gasser P, Kirchner K, Passie T (2015) LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects. J Psychopharmacol 29(1):57\u201368","journal-title":"J Psychopharmacol"},{"key":"6049_CR46","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jad.2017.05.048","volume":"221","author":"GM Goodwin","year":"2017","unstructured":"Goodwin GM et al (2017) Emotional blunting with antidepressant treatments: a survey among depressed patients. J Affect Disord 221:31\u201335","journal-title":"J Affect Disord"},{"issue":"9","key":"6049_CR47","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1038\/sj.npp.1300711","volume":"30","author":"PJ Gresch","year":"2005","unstructured":"Gresch PJ et al (2005) Behavioral tolerance to lysergic acid diethylamide is associated with reduced serotonin-2A receptor signaling in rat cortex. Neuropsychopharmacology 30(9):1693\u20131702","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"6049_CR48","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","volume":"187","author":"RR Griffiths","year":"2006","unstructured":"Griffiths RR et al (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl) 187(3):268\u201383 discussion 284-92","journal-title":"Psychopharmacology (Berl)"},{"issue":"4","key":"6049_CR49","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s00213-011-2358-5","volume":"218","author":"RR Griffiths","year":"2011","unstructured":"Griffiths RR et al (2011) Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology 218(4):649\u2013665","journal-title":"Psychopharmacology"},{"issue":"12","key":"6049_CR50","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","volume":"30","author":"RR Griffiths","year":"2016","unstructured":"Griffiths RR et al (2016) Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol 30(12):1181\u20131197","journal-title":"J Psychopharmacol"},{"issue":"1","key":"6049_CR51","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1177\/0269881117731279","volume":"32","author":"RR Griffiths","year":"2018","unstructured":"Griffiths RR et al (2018) Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. J Psychopharmacol 32(1):49\u201369","journal-title":"J Psychopharmacol"},{"key":"6049_CR52","first-page":"1","volume-title":"Advances in Substance Abuse","author":"RR Griffiths","year":"1980","unstructured":"Griffiths RR, Bigelow GE, Henningfield JE (1980) Similarities in animal and human drug-taking behavior. In: Mello NK (ed) Advances in Substance Abuse. JAI Press Inc, Greenwich, CT, pp 1\u201390"},{"key":"6049_CR53","volume-title":"Psychedelic drugs reconsidered","author":"L Grinspoon","year":"1979","unstructured":"Grinspoon L, Bakalar JB (1979) Psychedelic drugs reconsidered. Basic Books, New York xiv, 343 p"},{"issue":"2","key":"6049_CR54","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/00005053-199602000-00004","volume":"184","author":"CS Grob","year":"1996","unstructured":"Grob CS et al (1996) Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil. J Nerv Ment Dis 184(2):86\u201394","journal-title":"J Nerv Ment Dis"},{"issue":"1","key":"6049_CR55","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","volume":"68","author":"CS Grob","year":"2011","unstructured":"Grob CS et al (2011) Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry 68(1):71\u201378","journal-title":"Arch Gen Psychiatry"},{"key":"6049_CR56","doi-asserted-by":"crossref","unstructured":"Gukasyan N, Nayak SM (2021) Psychedelics, placebo effects, and set and setting: Insights from common factors theory of psychotherapy. Transcult Psychiatry 26:1363461520983684","DOI":"10.1177\/1363461520983684"},{"issue":"3","key":"6049_CR57","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S0376-8716(98)00129-X","volume":"53","author":"JH Halpern","year":"1999","unstructured":"Halpern JH, Pope HG Jr (1999) Do hallucinogens cause residual neuropsychological toxicity? Drug Alcohol Depend 53(3):247\u2013256","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"6049_CR58","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S0376-8716(02)00306-X","volume":"69","author":"JH Halpern","year":"2003","unstructured":"Halpern JH, Pope HG Jr (2003) Hallucinogen persisting perception disorder: what do we know after 50 years? Drug Alcohol Depend 69(2):109\u2013119","journal-title":"Drug Alcohol Depend"},{"issue":"8","key":"6049_CR59","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.biopsych.2005.06.038","volume":"58","author":"JH Halpern","year":"2005","unstructured":"Halpern JH et al (2005) Psychological and cognitive effects of long-term peyote use among Native Americans. Biol Psychiatry 58(8):624\u2013631","journal-title":"Biol Psychiatry"},{"key":"6049_CR60","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/7854_2016_457","volume":"36","author":"JH Halpern","year":"2018","unstructured":"Halpern JH, Lerner AG, Passie T (2018) A review of hallucinogen persisting perception disorder (HPPD) and an exploratory study of subjects claiming symptoms of HPPD. Curr Top Behav Neurosci 36:333\u2013360","journal-title":"Curr Top Behav Neurosci"},{"issue":"12","key":"6049_CR61","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1177\/0269881116677852","volume":"30","author":"I Hartogsohn","year":"2016","unstructured":"Hartogsohn I (2016) Set and setting, psychedelics and the placebo response: an extra-pharmacological perspective on psychopharmacology. J Psychopharmacol 30(12):1259\u20131267","journal-title":"J Psychopharmacol"},{"issue":"2","key":"6049_CR62","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00213-003-1640-6","volume":"172","author":"F Hasler","year":"2004","unstructured":"Hasler F et al (2004) Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. Psychopharmacology 172(2):145\u2013156","journal-title":"Psychopharmacology"},{"issue":"3","key":"6049_CR63","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s13181-016-0593-1","volume":"13","author":"CW Heise","year":"2017","unstructured":"Heise CW, Brooks DE (2017) Ayahuasca exposure: descriptive analysis of calls to US poison control centers from 2005 to 2015. J Med Toxicol 13(3):245\u2013248","journal-title":"J Med Toxicol"},{"issue":"7","key":"6049_CR64","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/bdi.13095","volume":"23","author":"HM Hendin","year":"2021","unstructured":"Hendin HM, Penn AD (2021) An episode of mania following self-reported ingestion of psilocybin mushrooms in a woman previously not diagnosed with bipolar disorder: A case report. Bipolar Disord 23(7):733\u2013735","journal-title":"Bipolar Disord"},{"issue":"3","key":"6049_CR65","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1177\/0269881114565653","volume":"29","author":"PS Hendricks","year":"2015","unstructured":"Hendricks PS et al (2015) Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. J Psychopharmacol 29(3):280\u2013288","journal-title":"J Psychopharmacol"},{"issue":"17","key":"6049_CR66","doi-asserted-by":"publisher","first-page":"e2022489118","DOI":"10.1073\/pnas.2022489118","volume":"118","author":"N Hesselgrave","year":"2021","unstructured":"Hesselgrave N et al (2021) Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. Proc Natl Acad Sci U S A 118(17):e2022489118","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"6049_CR67","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41386-019-0569-3","volume":"45","author":"F Holze","year":"2020","unstructured":"Holze F et al (2020) Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects. Neuropsychopharmacology 45(3):462\u2013471","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"6049_CR68","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/s41386-020-00883-6","volume":"46","author":"F Holze","year":"2021","unstructured":"Holze F et al (2021) Acute dose-dependent effects of lysergic acid diethylamide in a double blind placebo controlled study in healthy subjects. Neuropsychopharmacology 46(3):537\u2013544","journal-title":"Neuropsychopharmacology"},{"key":"6049_CR69","unstructured":"https:\/\/reporter.nih.gov\/search\/_NuFp5PaT0alcI1JOIRGVA\/project-details\/10127338"},{"key":"6049_CR70","unstructured":"Hyde R (1960) Psychological and social determinants of drug action. Dynamics of Psychiatric Drug Therapy. Sarwer-Foner G (ed) Springfield, pp 297\u2013315"},{"issue":"3","key":"6049_CR71","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1177\/0269881114568039","volume":"29","author":"PO Johansen","year":"2015","unstructured":"Johansen PO, Krebs TS (2015) Psychedelics not linked to mental health problems or suicidal behavior: a population study. J Psychopharmacol 29(3):270\u2013279","journal-title":"J Psychopharmacol"},{"issue":"6","key":"6049_CR72","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0269881108093587","volume":"22","author":"M Johnson","year":"2008","unstructured":"Johnson M, Richards W, Griffiths R (2008) Human hallucinogen research: guidelines for safety. J Psychopharmacol 22(6):603\u2013620","journal-title":"J Psychopharmacol"},{"issue":"1\u20133","key":"6049_CR73","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.drugalcdep.2011.10.029","volume":"123","author":"MW Johnson","year":"2012","unstructured":"Johnson MW, Sewell RA, Griffiths RR (2012) Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers. Drug Alcohol Depend 123(1\u20133):132\u2013140","journal-title":"Drug Alcohol Depend"},{"issue":"11","key":"6049_CR74","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/0269881114548296","volume":"28","author":"MW Johnson","year":"2014","unstructured":"Johnson MW et al (2014) Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol 28(11):983\u2013992","journal-title":"J Psychopharmacol"},{"issue":"1","key":"6049_CR75","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3109\/00952990.2016.1170135","volume":"43","author":"MW Johnson","year":"2017","unstructured":"Johnson MW, Garcia-Romeu A, Griffiths RR (2017) Long-term follow-up of psilocybin-facilitated smoking cessation. Am J Drug Alcohol Abuse 43(1):55\u201360","journal-title":"Am J Drug Alcohol Abuse"},{"key":"6049_CR76","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.neuropharm.2018.05.012","volume":"142","author":"MW Johnson","year":"2018","unstructured":"Johnson MW et al (2018) The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology 142:143\u2013166","journal-title":"Neuropharmacology"},{"issue":"46","key":"6049_CR77","doi-asserted-by":"publisher","first-page":"19575","DOI":"10.1073\/pnas.0905884106","volume":"106","author":"KA Jones","year":"2009","unstructured":"Jones KA et al (2009) Rapid modulation of spine morphology by the 5-HT2A serotonin receptor through kalirin-7 signaling. Proc Natl Acad Sci U S A 106(46):19575\u201319580","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"6049_CR78","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1177\/0269881112439253","volume":"26","author":"TS Krebs","year":"2012","unstructured":"Krebs TS, Johansen PO (2012) Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J Psychopharmacol 26(7):994\u20131002","journal-title":"J Psychopharmacol"},{"issue":"2","key":"6049_CR79","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/00005053-196808000-00008","volume":"147","author":"RJ Langs","year":"1968","unstructured":"Langs RJ, Barr HL (1968) Lysergic acid diethylamide (LSD-25) and schizophrenic reactions. A comparative study. J Nerv Ment Dis 147(2):163\u201372","journal-title":"J Nerv Ment Dis"},{"key":"6049_CR80","volume-title":"The psychedelic experience: a manual based on the Tibetan book of the dead","author":"T Leary","year":"1964","unstructured":"Leary T (1964) The psychedelic experience: a manual based on the Tibetan book of the dead. University Books, New York"},{"issue":"12","key":"6049_CR81","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1177\/0269881118793086","volume":"32","author":"JB Leonard","year":"2018","unstructured":"Leonard JB, Anderson B, Klein-Schwartz W (2018) Does getting high hurt? Characterization of cases of LSD and psilocybin-containing mushroom exposures to national poison centers between 2000 and 2016. J Psychopharmacol 32(12):1286\u20131294","journal-title":"J Psychopharmacol"},{"issue":"11","key":"6049_CR82","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1038\/npp.2017.86","volume":"42","author":"ME Liechti","year":"2017","unstructured":"Liechti ME (2017) Modern Clinical Research on LSD. Neuropsychopharmacology 42(11):2114\u20132127","journal-title":"Neuropsychopharmacology"},{"issue":"9\u201310","key":"6049_CR83","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/s00213-016-4453-0","volume":"234","author":"ME Liechti","year":"2017","unstructured":"Liechti ME, Dolder PC, Schmid Y (2017) Alterations of consciousness and mystical-type experiences after acute LSD in humans. Psychopharmacology (Berl) 234(9\u201310):1499\u20131510","journal-title":"Psychopharmacology (Berl)"},{"issue":"11","key":"6049_CR84","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1111\/j.1445-5994.2012.02955.x","volume":"42","author":"TH Lim","year":"2012","unstructured":"Lim TH, Wasywich CA, Ruygrok PN (2012) A fatal case of \u201cmagic mushroom\u201d ingestion in a heart transplant recipient. Intern Med J 42(11):1268\u20131269","journal-title":"Intern Med J"},{"issue":"11","key":"6049_CR85","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","volume":"23","author":"C Ly","year":"2018","unstructured":"Ly C et al (2018) Psychedelics promote structural and functional neural plasticity. Cell Rep 23(11):3170\u20133182","journal-title":"Cell Rep"},{"issue":"4","key":"6049_CR86","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/j.1468-5906.2012.01685.x","volume":"51","author":"KA Maclean","year":"2012","unstructured":"Maclean KA et al (2012) Factor analysis of the mystical experience questionnaire: a study of experiences occasioned by the hallucinogen psilocybin. J Sci Study Relig 51(4):721\u2013737","journal-title":"J Sci Study Relig"},{"issue":"7","key":"6049_CR87","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1038\/s41386-019-0324-9","volume":"44","author":"MK Madsen","year":"2019","unstructured":"Madsen MK et al (2019) Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology 44(7):1328\u20131334","journal-title":"Neuropsychopharmacology"},{"key":"6049_CR88","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-021-05876-x","author":"B Malcolm","year":"2021","unstructured":"Malcolm B, Thomas K (2021) Serotonin toxicity of serotonergic psychedelics. Psychopharmacology (Berl). https:\/\/doi.org\/10.1007\/s00213-021-05876-x","journal-title":"Psychopharmacology (Berl)"},{"issue":"11","key":"6049_CR89","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.4088\/JCP.v67n1110","volume":"67","author":"FA Moreno","year":"2006","unstructured":"Moreno FA et al (2006) Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry 67(11):1735\u201340","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"6049_CR90","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1080\/17512433.2021.1933434","volume":"14","author":"SD Muthukumaraswamy","year":"2021","unstructured":"Muthukumaraswamy SD, Forsyth A, Lumley T (2021) Blinding and expectancy confounds in psychedelic randomized controlled trials. Expert Rev Clin Pharmacol 14(9):1133\u20131152","journal-title":"Expert Rev Clin Pharmacol"},{"key":"6049_CR91","first-page":"285","volume-title":"Peyote hunt; the sacred journey of the Huichol Indians. Symbol, myth, and ritual series","author":"BG Myerhoff","year":"1974","unstructured":"Myerhoff BG (1974) Peyote hunt; the sacred journey of the Huichol Indians. Symbol, myth, and ritual series. Cornell University Press, Ithaca, p 285"},{"issue":"5","key":"6049_CR92","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1055\/a-1524-2794","volume":"54","author":"SM Nayak","year":"2021","unstructured":"Nayak SM et al (2021) Classic psychedelic coadministration with lithium, but not lamotrigine, is associated with seizures: an analysis of online psychedelic experience reports. Pharmacopsychiatry 54(5):240\u2013245","journal-title":"Pharmacopsychiatry"},{"issue":"7","key":"6049_CR93","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1177\/0269881118780713","volume":"32","author":"CR Nicholas","year":"2018","unstructured":"Nicholas CR et al (2018) High dose psilocybin is associated with positive subjective effects in healthy volunteers. J Psychopharmacol 32(7):770\u2013778","journal-title":"J Psychopharmacol"},{"issue":"2","key":"6049_CR94","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/pr.115.011478","volume":"68","author":"DE Nichols","year":"2016","unstructured":"Nichols DE (2016) Psychedelics. Pharmacol Rev 68(2):264\u2013355","journal-title":"Pharmacol Rev"},{"key":"6049_CR95","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.forsciint.2018.01.006","volume":"284","author":"DE Nichols","year":"2018","unstructured":"Nichols DE, Grob CS (2018) Is LSD toxic? Forensic Sci Int 284:141\u2013145","journal-title":"Forensic Sci Int"},{"issue":"2","key":"6049_CR96","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1021\/acsptsci.0c00192","volume":"4","author":"DE Olson","year":"2021","unstructured":"Olson DE (2021) The subjective effects of psychedelics may not be necessary for their enduring therapeutic effects. ACS Pharmacol Transl Sci 4(2):563\u2013567","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"1","key":"6049_CR97","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1590\/1516-4446-2014-1496","volume":"37","author":"L Osorio Fde","year":"2015","unstructured":"Osorio Fde L et al (2015) Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report. Braz J Psychiatry 37(1):13\u201320","journal-title":"Braz J Psychiatry"},{"issue":"4","key":"6049_CR98","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1017\/S0033291718001356","volume":"49","author":"F Palhano-Fontes","year":"2019","unstructured":"Palhano-Fontes F et al (2019) Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med 49(4):655\u2013663","journal-title":"Psychol Med"},{"key":"6049_CR99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2050324518767442","volume":"4","author":"T Passie","year":"2018","unstructured":"Passie T (2018) The early uses of MDMA (\u2018Ecstasy\u2019) in psychotherapy (1977\u20131985). Drug Science, Policy, and Law 4:1\u201319","journal-title":"Drug Science, Policy, and Law"},{"issue":"4","key":"6049_CR100","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1080\/1355621021000005937","volume":"7","author":"T Passie","year":"2002","unstructured":"Passie T, Seifert J, Schneider U, Emrich HM (2002) The pharmacology of psilocybin. Addict Biol. 7(4):357\u201364","journal-title":"Addict Biol."},{"issue":"4","key":"6049_CR101","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.euroneuro.2016.01.005","volume":"26","author":"T Pokorny","year":"2016","unstructured":"Pokorny T et al (2016) Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A\/2A agonist ergotamine on psilocybin-induced psychedelic experience. Eur Neuropsychopharmacol 26(4):756\u2013766","journal-title":"Eur Neuropsychopharmacol"},{"issue":"3","key":"6049_CR102","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.cub.2016.12.030","volume":"27","author":"KH Preller","year":"2017","unstructured":"Preller KH et al (2017) The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation. Curr Biol 27(3):451\u2013457","journal-title":"Curr Biol"},{"issue":"8","key":"6049_CR103","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/j.jvir.2008.05.008","volume":"19","author":"MV Raval","year":"2008","unstructured":"Raval MV et al (2008) Percutaneous transluminal angioplasty in the treatment of extensive LSD-induced lower extremity vasospasm refractory to pharmacologic therapy. J Vasc Interv Radiol 19(8):1227\u20131230","journal-title":"J Vasc Interv Radiol"},{"key":"6049_CR104","doi-asserted-by":"publisher","first-page":"974","DOI":"10.3389\/fphar.2017.00974","volume":"8","author":"L Roseman","year":"2017","unstructured":"Roseman L, Nutt DJ, Carhart-Harris RL (2017) Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front Pharmacol 8:974","journal-title":"Front Pharmacol"},{"key":"6049_CR105","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.neuropharm.2017.12.041","volume":"142","author":"L Roseman","year":"2018","unstructured":"Roseman L et al (2018) Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression. Neuropharmacology 142:263\u2013269","journal-title":"Neuropharmacology"},{"issue":"4","key":"6049_CR106","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1080\/09540261.2018.1482261","volume":"30","author":"S Ross","year":"2018","unstructured":"Ross S (2018) Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress. Int Rev Psychiatry 30(4):317\u2013330","journal-title":"Int Rev Psychiatry"},{"issue":"12","key":"6049_CR107","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","volume":"30","author":"S Ross","year":"2016","unstructured":"Ross S et al (2016) Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol 30(12):1165\u20131180","journal-title":"J Psychopharmacol"},{"issue":"1","key":"6049_CR108","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/JCP.0000000000000436","volume":"36","author":"RF Sanches","year":"2016","unstructured":"Sanches RF et al (2016) Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression: A SPECT Study. J Clin Psychopharmacol 36(1):77\u201381","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"6049_CR109","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/s13311-020-00962-y","volume":"18","author":"EA Schindler","year":"2021","unstructured":"Schindler EA, Sewell RA, Gottschalk CH, Luddy C, Flynn LT, Lindsey H, Pittman BP, Cozzi NV, D\u2019Souza DC (2021) Exploratory controlled study of the migraine-suppressing effects of psilocybin. Neurotherapeutics. 18(1):534\u201343","journal-title":"Neurotherapeutics."},{"key":"6049_CR110","first-page":"208","volume-title":"Plants of the gods: their sacred, healing, and hallucinogenic powers. Rev. and expanded ed","author":"RE Schultes","year":"2001","unstructured":"Schultes RE, Hofmann A, R\u00e4tsch C (2001) Plants of the gods: their sacred, healing, and hallucinogenic powers. Rev. and expanded ed. Healing Arts Press, Rochester, p 208"},{"issue":"10","key":"6049_CR111","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1097\/00005053-198410000-00001","volume":"172","author":"RJ Strassman","year":"1984","unstructured":"Strassman RJ (1984) Adverse reactions to psychedelic drugs. A review of the literature. J Nerv Ment Dis 172(10):577\u201395","journal-title":"J Nerv Ment Dis"},{"issue":"1\u20132","key":"6049_CR112","first-page":"121","volume":"73","author":"RJ Strassman","year":"1996","unstructured":"Strassman RJ (1996) Human psychopharmacology of N, N-dimethyltryptamine. Behav Brain Res 73(1\u20132):121\u2013124","journal-title":"Behav Brain Res"},{"issue":"2","key":"6049_CR113","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1001\/archpsyc.1994.03950020022002","volume":"51","author":"RJ Strassman","year":"1994","unstructured":"Strassman RJ et al (1994) Dose-response study of N, N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry 51(2):98\u2013108","journal-title":"Arch Gen Psychiatry"},{"issue":"8","key":"6049_CR114","doi-asserted-by":"publisher","first-page":"e12412","DOI":"10.1371\/journal.pone.0012412","volume":"5","author":"E Studerus","year":"2010","unstructured":"Studerus E, Gamma A, Vollenweider FX (2010) Psychometric evaluation of the altered states of consciousness rating scale (OAV). PLoS One 5(8):e12412","journal-title":"PLoS One"},{"issue":"11","key":"6049_CR115","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1177\/0269881110382466","volume":"25","author":"E Studerus","year":"2011","unstructured":"Studerus E et al (2011) Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol 25(11):1434\u20131452","journal-title":"J Psychopharmacol"},{"issue":"2","key":"6049_CR116","doi-asserted-by":"publisher","first-page":"e30800","DOI":"10.1371\/journal.pone.0030800","volume":"7","author":"E Studerus","year":"2012","unstructured":"Studerus E et al (2012) Prediction of psilocybin response in healthy volunteers. PLoS One 7(2):e30800","journal-title":"PLoS One"},{"key":"6049_CR117","doi-asserted-by":"publisher","unstructured":"Timmermann C, Watts R, Dupuis D (2020) Towards psychedelic apprenticeship: Developing a gentle touch for the mediation and validation of psychedelic-induced insights and revelations.\u00a0Transcult Psychiatry. https:\/\/doi.org\/10.31234\/osf.io\/j5768","DOI":"10.31234\/osf.io\/j5768"},{"issue":"8","key":"6049_CR118","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1523\/JNEUROSCI.17-08-02785.1997","volume":"17","author":"VA Vaidya","year":"1997","unstructured":"Vaidya VA et al (1997) 5-HT2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex. J Neurosci 17(8):2785\u20132795","journal-title":"J Neurosci"},{"issue":"17","key":"6049_CR119","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","volume":"9","author":"FX Vollenweider","year":"1998","unstructured":"Vollenweider FX et al (1998) Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport 9(17):3897\u20133902","journal-title":"NeuroReport"},{"issue":"5","key":"6049_CR120","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1177\/0022167817709585","volume":"57","author":"R Watts","year":"2017","unstructured":"Watts R, Day C, Krzanowski J, Nutt D, Carhart-Harris R (2017) Patients\u2019 accounts of increased \u201cconnectedness\u201d and \u201cacceptance\u201d after psilocybin for treatment-resistant deprerssion. J Human Psychol 57(5):520\u2013564","journal-title":"J Human Psychol"},{"issue":"2","key":"6049_CR121","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1021\/acsptsci.0c00194","volume":"4","author":"DB Yaden","year":"2021","unstructured":"Yaden DB, Griffiths RR (2021) The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects. ACS Pharmacol Transl Sci 4(2):568\u2013572","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"5","key":"6049_CR122","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1001\/jamapsychiatry.2020.3672","volume":"78","author":"DB Yaden","year":"2021","unstructured":"Yaden DB, Yaden ME, Griffiths RR (2021) Psychedelics in psychiatry-keeping the renaissance from going off the rails. JAMA Psychiat 78(5):469\u2013470","journal-title":"JAMA Psychiat"},{"issue":"2","key":"6049_CR123","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s00213-020-05692-9","volume":"238","author":"RJ Zeifman","year":"2021","unstructured":"Zeifman RJ et al (2021) Rapid and sustained decreases in suicidality following a single dose of ayahuasca among individuals with recurrent major depressive disorder: results from an open-label trial. Psychopharmacology 238(2):453\u2013459","journal-title":"Psychopharmacology"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-021-06049-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-021-06049-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-021-06049-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T03:05:46Z","timestamp":1654225546000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-021-06049-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,13]]},"references-count":123,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["6049"],"URL":"https:\/\/doi.org\/10.1007\/s00213-021-06049-6","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,13]]},"assertion":[{"value":"11 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DB: no conflicts. DH: Dr. Hellerstein has received research funding support from Compass Pathways for psilocybin studies and from Pfizer, Lilly, Takeda, GeneSight, Marinus, Relmada, and IntraCellular Therapies for other studies. He is on the scientific advisory board for Reset Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}